Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.35 |
| ▸ | PI4KA | P42356 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.35 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656840 | 1.00 | PIK3CA (0.43) | PIK3CAMTORGRM2SYKP2RX3 | |
| SCHEMBL24166480 | 0.86 | ALOX15 (0.46) | P2RX3KMT2AMEN1TDP1ALOX15 | |
| SCHEMBL30656834 | 0.86 | ALOX15 (0.46) | P2RX3KMT2AMEN1TDP1ALOX15 | |
| SCHEMBL30656795 | 0.84 | BRAF (0.41) | PIK3CASYKKMT2AMEN1BRAF | |
| SCHEMBL24165960 | 0.84 | BRAF (0.41) | PIK3CASYKKMT2AMEN1BRAF | |
| SCHEMBL24166503 | 0.84 | ALDH1A1 (0.43) | KMT2AMEN1TDP1BRAFMAPK1 | |
| SCHEMBL30656811 | 0.84 | ALDH1A1 (0.43) | KMT2AMEN1TDP1BRAFMAPK1 | |
| SCHEMBL24166121 | 0.83 | CLK1 (0.43) | GRM2P2RX3KMT2AMEN1TDP1 | |
| SCHEMBL30656848 | 0.83 | CLK1 (0.43) | GRM2P2RX3KMT2AMEN1TDP1 | |
| SCHEMBL24166155 | 0.83 | KMT2A (0.40) | SYKP2RX3KMT2AMEN1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| WO-2022003712-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | PIK3CA 2562/4885MTOR 730/4885GRM2 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.